董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean McClain | 男 | Chief Executive Officer and Director | 36 | 368.66万美元 | 1076.07 | 2025-07-07 |
| Mary Szela | -- | Director | -- | 36.75万美元 | 未持股 | 2025-07-07 |
| Menelas Pangalos | -- | Independent Director | -- | 未披露 | 未持股 | 2025-07-07 |
| Joseph Sirosh | -- | Independent Director | -- | 21.60万美元 | 未持股 | 2025-07-07 |
| Daniel A. Rabinovitsj | -- | Independent Director | -- | 23.76万美元 | 7.88 | 2025-07-07 |
| Frans Van Houten | 男 | Chairman of the Board | -- | 26.90万美元 | 6.79 | 2025-07-07 |
| Karen McGinnis | 女 | Independent Director | 59 | 24.01万美元 | 27.15 | 2025-07-07 |
| Menelas Pangalos | 男 | Independent Director | 59 | 24.56万美元 | 5.98 | 2025-07-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zachariah Jonasson | 男 | Chief Financial Officer and Chief Business Officer | 54 | 230.68万美元 | 71.53 | 2025-07-07 |
| Sean McClain | 男 | Chief Executive Officer and Director | 36 | 368.66万美元 | 1076.07 | 2025-07-07 |
| Todd Bedrick | -- | Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Shelby J. Walker | -- | Chief Legal Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Andreas Busch | -- | Chief Innovation Officer | -- | 156.11万美元 | 182.93 | 2025-07-07 |
董事简历
中英对照 | 中文 | 英文- Sean McClain
-
Sean McClain是我们的创始人，自2011年8月以来担任我们的首席执行官，自2020年10月Absci Corporation成立以来担任我们的董事会成员，自成立以来担任其前身Absci LLC的管理成员。McClain先生还担任Oregon Bioscience Association，Oregon Bioscience Incubator和Oregon Translational研究与开发Institute Otradi以及Life Science Washington的董事会成员。McClain先生于2011年获得亚利桑那大学分子和细胞生物学理学学士学位。
Sean McClain is Founder and has served as Chief Executive Officer since August 2011 and a member of board of directors since the formation of Absci Corporation in October 2020 and a managing member of its predecessor, AbSci LLC, since inception. Mr. McClain also serves as a board member for the Oregon Bioscience Association, Oregon Bioscience Incubator and Oregon Translational Research and Development Institute OTRADI, and Life Science Washington. Mr. McClain holds a Bachelor of Science degree in Molecular and Cellular Biology in 2011 from the University of Arizona. - Sean McClain是我们的创始人，自2011年8月以来担任我们的首席执行官，自2020年10月Absci Corporation成立以来担任我们的董事会成员，自成立以来担任其前身Absci LLC的管理成员。McClain先生还担任Oregon Bioscience Association，Oregon Bioscience Incubator和Oregon Translational研究与开发Institute Otradi以及Life Science Washington的董事会成员。McClain先生于2011年获得亚利桑那大学分子和细胞生物学理学学士学位。
- Sean McClain is Founder and has served as Chief Executive Officer since August 2011 and a member of board of directors since the formation of Absci Corporation in October 2020 and a managing member of its predecessor, AbSci LLC, since inception. Mr. McClain also serves as a board member for the Oregon Bioscience Association, Oregon Bioscience Incubator and Oregon Translational Research and Development Institute OTRADI, and Life Science Washington. Mr. McClain holds a Bachelor of Science degree in Molecular and Cellular Biology in 2011 from the University of Arizona.
- Mary Szela
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Menelas Pangalos
-
暂无中文简介
Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London. -
暂无中文简介
- Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London.
- Joseph Sirosh
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Daniel A. Rabinovitsj
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Frans Van Houten
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Karen McGinnis
-
Karen McGinnis，自2013年6月担任首席财务官。在加入本公司之前，从2009年11月到2013年5月她在半导体设备行业的一家为光刻工具制造商提供光源的全球开发、制造和营销商——Cymer公司的副总裁、财务总监兼首席会计官。McGinnis女士受雇于一家信息技术硬件、软件和服务的全球财富500强的供应商，并从2006年9月到2009年3月担任首席会计官，并从 2001年到2006年9月担任财务高级副总裁。McGinnis女士是一名注册会计师，并获得俄克拉荷马大学（he University of Oklahoma）会计学士学位。
Karen McGinnis has served as a member of board of directors since August 2020. Ms. McGinnis also serves as an Independent Director of Alphatec Holdings, Inc. since June 2019 and of BioSplice Therapeutics, Inc. since March 2021. She was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement on April 2 2021. Ms. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017 the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc. from September 2006 until March 2009 its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. From 1997 to 2000 she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as its Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor's degree in Accounting from the University of Oklahoma in 1989. - Karen McGinnis，自2013年6月担任首席财务官。在加入本公司之前，从2009年11月到2013年5月她在半导体设备行业的一家为光刻工具制造商提供光源的全球开发、制造和营销商——Cymer公司的副总裁、财务总监兼首席会计官。McGinnis女士受雇于一家信息技术硬件、软件和服务的全球财富500强的供应商，并从2006年9月到2009年3月担任首席会计官，并从 2001年到2006年9月担任财务高级副总裁。McGinnis女士是一名注册会计师，并获得俄克拉荷马大学（he University of Oklahoma）会计学士学位。
- Karen McGinnis has served as a member of board of directors since August 2020. Ms. McGinnis also serves as an Independent Director of Alphatec Holdings, Inc. since June 2019 and of BioSplice Therapeutics, Inc. since March 2021. She was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement on April 2 2021. Ms. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017 the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc. from September 2006 until March 2009 its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. From 1997 to 2000 she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as its Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor's degree in Accounting from the University of Oklahoma in 1989.
- Menelas Pangalos
-
Menelas Pangalos，在担任早期研发执行副总裁（2010-2018）之后，曾担任阿斯利康生物制药研发执行副总裁（2019-2024）。他之前的职位包括辉瑞（Pfizer）的高级副总裁（2008-2010）和惠氏（Wyeth）的神经科学副总裁（2003-2008）。他是一位杰出的科学家，是英国皇家学会、英国医学科学院、英国皇家生物学会和剑桥克莱尔霍尔学会的会员。他于2024年加入Absci公司董事会。他持有伦敦帝国理工学院生物化学和分子生物学学士学位，以及伦敦大学学院神经药理学博士学位。
Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London. - Menelas Pangalos，在担任早期研发执行副总裁（2010-2018）之后，曾担任阿斯利康生物制药研发执行副总裁（2019-2024）。他之前的职位包括辉瑞（Pfizer）的高级副总裁（2008-2010）和惠氏（Wyeth）的神经科学副总裁（2003-2008）。他是一位杰出的科学家，是英国皇家学会、英国医学科学院、英国皇家生物学会和剑桥克莱尔霍尔学会的会员。他于2024年加入Absci公司董事会。他持有伦敦帝国理工学院生物化学和分子生物学学士学位，以及伦敦大学学院神经药理学博士学位。
- Menelas Pangalos,served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca (2019–2024) after leading as EVP of Early R&D (2010–2018). His prior roles include SVP at Pfizer (2008–2010) and VP of Neuroscience at Wyeth (2003–2008). A distinguished scientist, he is a Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Biology, and Clare Hall, Cambridge. He joined Absci Corporation's board in 2024. He holds a BSc in Biochemistry and Molecular Biology from Imperial College London and a PhD in Neuropharmacology from University College London.
高管简历
中英对照 | 中文 | 英文- Zachariah Jonasson
Zachariah Jonasson自2016年4月起担任公司董事会成员。他拥有超过25年的风险投资和公司运营经验。Jonasson博士目前是Phoenix Venture Partners LLC PVP（他于2010年8月共同创立的风险投资公司）的管理普通合伙人。乔纳森博士领导PVP公司的生物技术投资战略，并参与了PVP公司所有的风险投资和种子基金的募集。除了在ABSCI董事会任职外，Jonasson博士还担任PVP投资组合公司Green Theme Technologies，Inc.、Reform Biologics，LLC、Autonomic Materials，Inc.的董事。Sentinel Monitoring Systems，Inc.和L7Informatics，Inc.他还任职于俄勒冈州转化研究与开发研究所（OTRADI）的董事会，也曾任职于俄勒冈州纳米科学和微技术研究所（ONAMI）的商业化委员会，该委员会是俄勒冈州创新集群（OIC）的咨询委员会，在此之前，Jonasson博士是Reform Biologics，LLC的联合创始人兼首席执行官，在职业生涯早期是Crop Enhancement，LLC的联合创始人兼业务开发副总裁，British Columbia大学生命科学研究所顾问委员会成员，Jonasson博士是Seaflower Ventures（一家投资于生物技术领域的早期风险投资公司）的普通合伙人和考夫曼研究员，在那里他领导、管理和担任该公司的几个投资项目的董事会或董事会观察员，包括Serenex，Inc.和Valeritas，Inc.1995年，他在乔治敦大学（Georgetown University）获得理学学士学位，在那里他是罗兹奖学金的决赛选手，2003年，他在哈佛大学（Harvard University）获得AM和博士学位，在那里他是萨克勒学者。他曾在哈佛商学院（Harvard Business School）共同教授市场营销课程，也曾在哈佛大学（Harvard University）担任教师。在研究生院之前，Jonasson博士是联邦储备系统理事会的研究员。
Zachariah Jonasson has served as a member of the Company's board of directors since April 2016. He has over 25 years of experience in venture capital and company operations. Dr. Jonasson is currently a Managing General Partner of Phoenix Venture Partners LLC PVP, a venture capital firm he co-founded in August 2010. Dr. Jonasson leads PVP's investment strategy in biotechnology and has been involved in raising all of PVP's venture capital and seed funds. In addition to serving on the board of Absci, Dr. Jonasson serves as a director on the boards of PVP portfolio companies Green Theme Technologies, Inc., ReForm Biologics, LLC, Autonomic Materials, Inc. Sentinel Monitoring Systems, Inc., and L7 Informatics, Inc. He also serves on the board of the Oregon Translational Research and Development Institute (OTRADI) and has served on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), the Advisory Board for the Oregon Innovation Cluster (OIC), and the Advisory Board of the Life Sciences Institute at the University of British Columbia Previously, Dr. Jonasson was a co-founder and Chief Executive Officer of ReForm Biologics, LLC and a co-founder and VP of Business Development of Crop Enhancement, LLC Earlier in his career, Dr. Jonasson was a General Partner and Kauffman Fellow at Seaflower Ventures, an early-stage venture capital firm investing in the biotechnology sector, where he led, managed and held board or board observer roles at several of the firm's investments, including Serenex, Inc. and Valeritas, Inc. Dr. Jonasson earned a Bachelor of Science from Georgetown University in 1995 where he was a Rhodes Scholarship Finalist, and an AM and PhD from Harvard University in 2003 where he was a Sackler Scholar. He has co-taught a marketing course at Harvard Business School as well as served as a Teaching Fellow at Harvard University. Prior to graduate school, Dr. Jonasson was a Research Associate at the Board of Governors of the Federal Reserve System.- Zachariah Jonasson自2016年4月起担任公司董事会成员。他拥有超过25年的风险投资和公司运营经验。Jonasson博士目前是Phoenix Venture Partners LLC PVP（他于2010年8月共同创立的风险投资公司）的管理普通合伙人。乔纳森博士领导PVP公司的生物技术投资战略，并参与了PVP公司所有的风险投资和种子基金的募集。除了在ABSCI董事会任职外，Jonasson博士还担任PVP投资组合公司Green Theme Technologies，Inc.、Reform Biologics，LLC、Autonomic Materials，Inc.的董事。Sentinel Monitoring Systems，Inc.和L7Informatics，Inc.他还任职于俄勒冈州转化研究与开发研究所（OTRADI）的董事会，也曾任职于俄勒冈州纳米科学和微技术研究所（ONAMI）的商业化委员会，该委员会是俄勒冈州创新集群（OIC）的咨询委员会，在此之前，Jonasson博士是Reform Biologics，LLC的联合创始人兼首席执行官，在职业生涯早期是Crop Enhancement，LLC的联合创始人兼业务开发副总裁，British Columbia大学生命科学研究所顾问委员会成员，Jonasson博士是Seaflower Ventures（一家投资于生物技术领域的早期风险投资公司）的普通合伙人和考夫曼研究员，在那里他领导、管理和担任该公司的几个投资项目的董事会或董事会观察员，包括Serenex，Inc.和Valeritas，Inc.1995年，他在乔治敦大学（Georgetown University）获得理学学士学位，在那里他是罗兹奖学金的决赛选手，2003年，他在哈佛大学（Harvard University）获得AM和博士学位，在那里他是萨克勒学者。他曾在哈佛商学院（Harvard Business School）共同教授市场营销课程，也曾在哈佛大学（Harvard University）担任教师。在研究生院之前，Jonasson博士是联邦储备系统理事会的研究员。
- Zachariah Jonasson has served as a member of the Company's board of directors since April 2016. He has over 25 years of experience in venture capital and company operations. Dr. Jonasson is currently a Managing General Partner of Phoenix Venture Partners LLC PVP, a venture capital firm he co-founded in August 2010. Dr. Jonasson leads PVP's investment strategy in biotechnology and has been involved in raising all of PVP's venture capital and seed funds. In addition to serving on the board of Absci, Dr. Jonasson serves as a director on the boards of PVP portfolio companies Green Theme Technologies, Inc., ReForm Biologics, LLC, Autonomic Materials, Inc. Sentinel Monitoring Systems, Inc., and L7 Informatics, Inc. He also serves on the board of the Oregon Translational Research and Development Institute (OTRADI) and has served on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), the Advisory Board for the Oregon Innovation Cluster (OIC), and the Advisory Board of the Life Sciences Institute at the University of British Columbia Previously, Dr. Jonasson was a co-founder and Chief Executive Officer of ReForm Biologics, LLC and a co-founder and VP of Business Development of Crop Enhancement, LLC Earlier in his career, Dr. Jonasson was a General Partner and Kauffman Fellow at Seaflower Ventures, an early-stage venture capital firm investing in the biotechnology sector, where he led, managed and held board or board observer roles at several of the firm's investments, including Serenex, Inc. and Valeritas, Inc. Dr. Jonasson earned a Bachelor of Science from Georgetown University in 1995 where he was a Rhodes Scholarship Finalist, and an AM and PhD from Harvard University in 2003 where he was a Sackler Scholar. He has co-taught a marketing course at Harvard Business School as well as served as a Teaching Fellow at Harvard University. Prior to graduate school, Dr. Jonasson was a Research Associate at the Board of Governors of the Federal Reserve System.
- Sean McClain
Sean McClain是我们的创始人，自2011年8月以来担任我们的首席执行官，自2020年10月Absci Corporation成立以来担任我们的董事会成员，自成立以来担任其前身Absci LLC的管理成员。McClain先生还担任Oregon Bioscience Association，Oregon Bioscience Incubator和Oregon Translational研究与开发Institute Otradi以及Life Science Washington的董事会成员。McClain先生于2011年获得亚利桑那大学分子和细胞生物学理学学士学位。
Sean McClain is Founder and has served as Chief Executive Officer since August 2011 and a member of board of directors since the formation of Absci Corporation in October 2020 and a managing member of its predecessor, AbSci LLC, since inception. Mr. McClain also serves as a board member for the Oregon Bioscience Association, Oregon Bioscience Incubator and Oregon Translational Research and Development Institute OTRADI, and Life Science Washington. Mr. McClain holds a Bachelor of Science degree in Molecular and Cellular Biology in 2011 from the University of Arizona.- Sean McClain是我们的创始人，自2011年8月以来担任我们的首席执行官，自2020年10月Absci Corporation成立以来担任我们的董事会成员，自成立以来担任其前身Absci LLC的管理成员。McClain先生还担任Oregon Bioscience Association，Oregon Bioscience Incubator和Oregon Translational研究与开发Institute Otradi以及Life Science Washington的董事会成员。McClain先生于2011年获得亚利桑那大学分子和细胞生物学理学学士学位。
- Sean McClain is Founder and has served as Chief Executive Officer since August 2011 and a member of board of directors since the formation of Absci Corporation in October 2020 and a managing member of its predecessor, AbSci LLC, since inception. Mr. McClain also serves as a board member for the Oregon Bioscience Association, Oregon Bioscience Incubator and Oregon Translational Research and Development Institute OTRADI, and Life Science Washington. Mr. McClain holds a Bachelor of Science degree in Molecular and Cellular Biology in 2011 from the University of Arizona.
- Todd Bedrick
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Shelby J. Walker
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Andreas Busch
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介